# Early Aldo Blockade in Subclinical PA

> **NCT07727252** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Xinjiang Medical University** · enrollment: 880 (estimated)

## Conditions studied

- Subclinical Primary Aldosteronism

## Interventions

- **DRUG:** Eplerenone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07727252
- **Lead sponsor:** Xinjiang Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2029-08-01
- **Final completion:** 2029-08-01
- **Target enrollment:** 880 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07727252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07727252, "Early Aldo Blockade in Subclinical PA". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07727252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*